Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

ALZHEIMER DISEASE

Ventricular enlargement caused by aducanumab

Nature Reviews Neurology volume 18, pages 383–384 (2022)Cite this article

Subjects

A recent publication reveals progressive, dose-dependent ventricular enlargement in the brains of patients with early Alzheimer disease who were treated with the FDA-approved drug aducanumab. Aducanumab joins a growing list of anti-amyloid-β therapies for which there is evidence that they cause accelerated neurodegeneration; extended follow-up studies are required to determine whether aducanumab causes progressive brain damage.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J. Prev. Alzheimers Dis. https://doi.org/10.14283/jpad.2022.30 (2022).

    Article  PubMed  Google Scholar 

  2. Massie, T., Jin, K., Wang, S. J. & Hung, J. BLA761175: Aduhelm (Aducanumab) Statistical Review https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761178Orig1s000StatR_Redacted.pdf (FDA Centre for Drug Evaluation and Research, 2021).

  3. Cavazzoni, P. BLA761178: Aduhelm (Aducanumab) Memo https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/Aducanumab_BLA761178_Cavazzoni_2021_06_07.pdf (FDA Centre for Drug Evaluation and Research, 2021).

  4. Ayton, S. & Bush, A. I. β-amyloid: the known unknowns. Ageing Res. Rev. 65, 101212 (2021).

    Article  CAS  Google Scholar 

  5. Ayton, S. Brain volume loss due to donanemab. Eur. J. Neurol. 28, e67–e68 (2021).

    Article  Google Scholar 

  6. Ayton, S., Faux, N. G. & Bush, A. I. Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE. Nat. Commun. 6, 6760 (2015).

    Article  CAS  Google Scholar 

  7. Novak, G. et al. Changes in brain volume with bapineuzumab in mild to moderate Alzheimer’s disease. J. Alzheimers Dis. 49, 1123–1134 (2016).

    Article  CAS  Google Scholar 

  8. Liu, E. et al. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 85, 692–700 (2015).

    Article  CAS  Google Scholar 

  9. Krudys, K. BLA761178: Aduhelm (Aducanumab) Clinical Review(s) https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761178Orig1s000MedR_Redacted.pdf (FDA Center for Drug Evaluation and Research, 2021).

Download references

Author information

Authors and Affiliations

  1. Melbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia

    Scott Ayton

Authors
  1. Scott Ayton
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Scott Ayton.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ayton, S. Ventricular enlargement caused by aducanumab. Nat Rev Neurol 18, 383–384 (2022). https://doi.org/10.1038/s41582-022-00660-7

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41582-022-00660-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research